Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Presentation (August 2025)
32 slides from Faron Pharmaceuticals Oy's investor presentation, August 2025
Slide 1: Faron Pharmaceuticals Ltd Non-confidential corporate deck
August 2025 Faron Pharmaceuticals Ltd Non-confidential corporate deck 1 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Management
Management World-leading science with a comprehensive oncology drug development background Juho Jalkanen Maija Hollmén Yrjö Wichmann Petri Bono Ralph Hughes CEO CSO CFO CMO CBO Turku, Finland 25 2007 Global Headquarters Employees Year Founded FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORA
Slide 4: Scientific Advisory Board
Scientific Advisory Board Over a hundred years of combined experience in clinical practice and oncology drug development Toni Choueiri, MD, FASCO Naval G. Daver, MD Professor Professor Harvard, USA MD Anderson, CCC Tom Powles, MBBS, MRCP, MD Mika Kontro, MD, PhD Professor Adjunct Professor Barts Can
Slide 5: Harnessing the power of Clever-1 to conquer high-risk myelodysplastic syndrome
Harnessing the power of Clever-1 to conquer high-risk myelodysplastic syndrome ▪ Refractory/relapsed High-risk myelodysplastic syndrome (r/r HR MDS) is one of the deadliest of all cancers ▪ Bexmarilimab is a first-in-class anti-CLEVER-1, a master immunosuppressive receptor on myeloid cells and leuke
Slide 6: The Clever-1 target is highly expressed in myelodysplastic syndrome and acute myeloid leukemia
The Clever-1 target is highly expressed in myelodysplastic syndrome and acute myeloid leukemia Clever-1 Clever-1 expression in Finnish biobank samples from patients with HaemOnc malignancies ▪ A scavenger receptor expressed by leukemic myeloid cells and immunosuppressive macrophage B-ALL BCL/TCL pop
Slide 7: Clever-1 – a novel macrophage immune checkpoint
Clever-1 – a novel macrophage immune checkpoint Bexmarilimab mode of action 1 Bexmarilimab deactivates the energy production of CLEVER-1 is an immunosuppressive receptor on macrophages immune cells, responsible for 3 the cancer cells, enabling existing therapies. (ie. AZA), eliminating infected or c
Slide 8: Faron's oncology pipeline
Faron’s oncology pipeline Treatment Indication(s) Phase of Development Anticipated Key Milestones Preclinical Phase I Phase II Phase III Single-Agent Advanced solid tumors ▪ Completed Bexmarilimab FARON SPONSORED MATINS (First in Human, single agent) Haematology r/r MDS ▪ Confirmatory Phase III in 1
Slide 9: BEXMAB Phase II Data
BEXMAB PHASE II DATA 9 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 10: BEXMAB study design
BEXMAB study design Study population Phase I dose escalation based on BOIN design, 1.0, 3.0 ▪ MDS: treatment naive intermediate, high/very high –risk and 6.0mg/kg bexmarilimab. ▪ MDS: failure to HMA (r/r) Phase II initiated in r/r (HMA-failed) HR MDS, at dose ▪ Relapsed/refractory (r/r) AML optimiza
Slide 11: The complex and hard to treat r/r MDS patients showed a strong response to bexmarilimab
The complex and hard to treat r/r MDS patients showed a strong response to bexmarilimab June ’25 Data-cut n (%) Total Pt N = 32 IWG2006 CR 2 (6) PR 2 (6) Best change in bone marrow blast count by patient mCR 13 (41) HI 3 (9) SD 8 (25) Pending 4 (13) ORR (% of evaluable, n=32) 63% ★ Early evaluation!
Slide 12: r/r MDS patients experienced an estimated mOS of 13.4 months
r/r MDS patients experienced an estimated mOS of 13.4 months compared to the historical 5–6 months survival r/r HR MDS (n=32) ▪ Median follow-up: 6.9 months; 95% CI 4.8-15.2 months ▪ mOS estimate: 13.4 months; 95% CI 4.8 months-not reached ▪ Median duration of treatment: 5.6 months; 95% CI 2.8- 11.8
Slide 13: Frontline HR MDS patients showed a very strong response to bexmarilimab
Frontline HR MDS patients showed a very strong response to bexmarilimab even in a severity-enriched population August’25 Data-Cut n (%) Total Pt N=21 IWG 2006 CR 9 (43%) PR 1 (5%) mCR 5 (24%) HI 2 (10%) SD 2 (10%) No Response / 2 (10%) Progressive Disease ORR (% of evaluable, n=21) 81% ★ 35% of eval
Slide 14: Bexmarilimab's excellent safety profile allows hard-to-treat patients the opportunity to receive treatment
Bexmarilimab’s excellent safety profile allows hard-to- treat patients the opportunity to receive treatment Most common TEAEs Total (n=53) Gr 1-2 Gr 3-5 ▪ 7 (13.2%) discontinuations due to any TEAE n (%) Constipation 19 (35.9) 19 (35.9) 0 ▪ 1 (1.9%) discontinuation due to bexmarilimab-related AE Neu
Slide 15: Why give another myelosuppressive and toxic drug to already frail patients?
Why give another myelosuppressive and toxic drug to already frail and deeply cytopenic patients? Bex has an improved safety profile with potential for hematological recovery Bcl2: 43%-88% CD47: 36% Failed Assets TIM3: 62% Bcl2: 19%-71% CD47: 30%-79% Bexmarilimab Bcl2: 19%-65% Bcl2: 10%-65% CD47: 46%
Slide 16: HR MDS Development Plan
HR MDS DEVELOPMENT PLAN 16 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 17: FDA Advice: One Phase III for frontline and r/r HR MDS
FDA Advice: One Phase III for frontline and r/r HR MDS Proposed development by the FDA for Bex in the treatment of HR MDS (both 1L and r/r) Impact of FDA advice • One single Phase 3 for both frontline and r/r HR MDS • A separate Phase 3 is not needed for r/r MDS • Current BEXMAB Phase 2 is the appro
Slide 18: Development plan for HR MDS per FDA guidance
Development plan for HR MDS per FDA guidance 2024 2025 2026 2027 2028 H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 PHASE II PHASE III & BLA Full P1/P2 Full P1/P2 Survival Readout Analysis Phase 2 dose optimization (n=32) R/R MDS r/r MDS Accelerated MDS FDA Approval r/r MDS AA MDS FDA Orphan Drug FDA EOP2 Submissio
Slide 19: Bexmarilimab phase III study design: FDA EOP2 meeting coming up
Bexmarilimab phase III study design: FDA End of Phase 2 (EOP2) meeting coming up Planned BEXMAB-02 Frontline MDS Phase III study design and regulatory milestones based on previous FDA feedback: for discussion at EOP2 meeting Discussion points with FDA bexmarilimab bexmarilimab 3 mg/kg + azacitidine
Slide 20: MDS Landscape
MDS LANDSCAPE 20 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 21: The market opportunity in HR MDS
The market opportunity in HR MDS HR MDS represents a significant growing market with an un-tapped area especially in r/r MDS MDS market growth r/r MDS patient journey2) Estimated worldwide indication sales by year (USDbn)1) 180-510k MDS patients in the US & EU3) ! 50% 50% As a new, well tolerated ef
Slide 22: US payer insights: price of $18-25k per month
Based on US payer insights, a price of $18-25k per month is realistic and achievable in frontline and r/r HR MDS 22 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 23: HR MDS represents a significant untapped market with high up-take potential
HR MDS represents a significant untapped market with high up-take potential 18000 16000 14000 Number of Patients Treated EU5 12000 10000 USA 8000 6000 4000 2000 0 1. PharmaVentures market access report 23 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 24: Outlook
OUTLOOK 24 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 25: Outlook
Outlook Moving into phase III and investigator initiated solid tumor phase II trials End of Q2 Q3 2025 H2 2025 H1 2026 H2 2026 Detailed FDA EOP2 Phase III First-patient-in First-patient-in First efficacy Phase II data meeting preparations for solid for BEXMAB readouts from presented at according to
Slide 26: Bexmarilimab in Solid Tumors
BEXMARILIMAB IN SOLID TUMORS 26 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 27: Proof of principle of modulating the tumor microenvironment (TME)
Proof of principle of modulating the tumor microenvironment (TME) Phase 1/2 First-in-Human MATINS Trial Highlights • 216 patients treated across 10 different cancer types • Targeting Clever-1 with bexmarilimab is well tolerated, RP2D 1mg/kg Q3W supported by the FDA • Bex converts intratumoral macrop
Slide 28: Bexmarilimab – a drug for cold (IFNg low) tumors
Bexmarilimab – a drug for cold (IFNg low) tumors As single agents bexmarilimab and anti-PD-1s benefit opposite melanoma populations Bex treated melanoma patients according Anti-PD1 treated melanoma patients according to to IFN gamma status3 IFN gamma status1,2 Pts achieving disease control Pts not a
Slide 29: Appendix
APPENDIX 29 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 30: Demographics – frontline MDS
Demographics – frontline MDS Patient baseline characteristics Total (N=21) Age (years); median (range) 72 (53-81) ECOG PS, n (%) 0 4 (19) 1 15 (71.4) 2 2 (9.5) IPSS-R Intermediate (>3– ≤4.5 points) 7 (33.3) High (>4.5 - ≤6 points) 6 (28.6) Very high (> 6 points) 8 (38.1) Baseline blast percentage <5
Slide 31: Demographics – r/r MDS
Demographics – r/r MDS Patient baseline characteristics Total (N=32) Age (years); median (range) 74 (52-87) ECOG PS, n (%) 0 9 (28.1) 1 20 (62.5) 2 3 (9.4) IPSS-R Intermediate (>3– ≤4.5 points) 6 (18.8) High (>4.5 - ≤6 points) 11 (34.4) Very high (> 6 points) 15 (46.9) Mutations, n (%) TP53 13 (40.6
Slide 32: 3 mg/kg offers optimal efficacy and safety profile
3 mg/kg offers optimal efficacy and safety profile 1mg/kg Doublet 3mg/kg Doublet (N=25), 6mg/kg Doublet (N=24), n Adverse Events Total (N=53), n (%) (N=4), n (%) n (%) (%) • Good safety profile Total AEs 53 (100) 4 (100) 25 (100) 24 (100) maintained 52 (98) 4 (100) 24 (96) 24 (100) • No G5 Bex-Relat
Faron Pharmaceuticals — Investor Presentation (August 2025) on 6ix